Long Position on SUPN @ $56.50 on 5/30/2018 (Momentum)

Supernus Pharmaceuticals, Inc. (SUPN) is a specialty pharmaceutical company. 

The firm focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.

It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD.

It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression.

The company markets its products through wholesalers and pharmaceutical distributors. Shares have formed a bullish "flag" following its recent earnings report. Higher share prices are expected for this stock.

Entry Point: $56.50

Stop Loss: $53.70

52-Weeks Trading Range: $33.30 - $59.05

Target Price: $62.15

Updates

8/23/2018 2:26:08 PM

SUPN closed at $44.83

Position closed on 8/23/2018 at price of $44.83 with a -20.65% loss in 85 days.

Back to Portfolio